IRulya Therapeutics Inc.: SILVERARC CAPITAL MANAGEMENT, LLC discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Silverarc Capital Management LLC disclosed a stake exceeding 5% in IRulya Therapeutics Inc. via a Schedule 13G filing with the SEC (accession 0001104659-26-127344). The passive-investment disclosure signals a new institutional holder above the 5% threshold that triggers mandatory reporting. The exact share count and percentage were not specified in the filing headline. Investors will watch for further 13G/13D amendments to clarify whether Silverarc's position is passive or activist.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Silverarc Capital Management, LLC, IRulya Therapeutics Inc.